Lei Lv Selected Research

Dioxygenases

1/2022	TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
1/2020	USP15 suppresses tumor immunity via deubiquitylation and inactivation of TET2.
1/2019	Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
2/2015	WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
1/2015	CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lei Lv Research Topics

Disease

41	Neoplasms (Cancer) 06/2022 - 09/2009
10	Inflammation (Inflammations) 01/2022 - 04/2015
7	Urinary Bladder Neoplasms (Bladder Cancer) 06/2015 - 01/2011
5	Infections 01/2022 - 01/2018
5	Myocardial Infarction 01/2022 - 01/2012
4	Hepatocellular Carcinoma (Hepatoma) 06/2022 - 03/2008
4	Breast Neoplasms (Breast Cancer) 01/2022 - 02/2017
4	Fibrosis (Cirrhosis) 10/2021 - 07/2012
4	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 01/2015
4	Carcinoma (Carcinomatosis) 01/2020 - 03/2012
3	Neoplasm Metastasis (Metastasis) 03/2022 - 02/2017
3	Atherosclerosis 05/2021 - 01/2018
3	Melanoma (Melanoma, Malignant) 01/2021 - 01/2019
3	Lung Neoplasms (Lung Cancer) 01/2020 - 08/2016
3	Stroke (Strokes) 01/2019 - 06/2011
3	Neointima 01/2017 - 08/2013
3	Wounds and Injuries (Trauma) 02/2016 - 01/2015
3	Carcinogenesis 02/2015 - 06/2011
3	Hyperplasia 01/2015 - 08/2012
2	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 09/2014
2	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 06/2016
2	Spontaneous Abortion (Miscarriage) 08/2021 - 04/2021
2	Esophageal Squamous Cell Carcinoma 03/2021 - 01/2019
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 12/2012
2	Rabies (Hydrophobia) 01/2021 - 08/2020
2	Neuroinflammatory Diseases 04/2020 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 04/2011
2	Colonic Neoplasms (Colon Cancer) 01/2019 - 01/2018
2	Asthma (Bronchial Asthma) 11/2018 - 01/2018
2	Reperfusion Injury 01/2018 - 01/2012
2	Arteriovenous Fistula 01/2017 - 04/2016
2	Ulcer 02/2016 - 01/2015
2	Diabetic Foot 02/2016 - 01/2015
2	Substance-Related Disorders (Drug Abuse) 01/2014 - 12/2012
2	Infarction (Infarctions) 07/2012 - 01/2012
2	Spinal Cord Injuries (Spinal Cord Injury) 02/2012 - 06/2011
1	Malaria 11/2022
1	Angina Pectoris 01/2022
1	Hypertrophy 01/2022

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 06/2022 - 02/2012
8	MicroRNAs (MicroRNA)IBA 01/2021 - 03/2015
7	EnzymesIBA 01/2022 - 01/2014
7	Pharmaceutical PreparationsIBA 10/2021 - 05/2012
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2013
5	InterferonsIBA 11/2022 - 01/2019
5	DioxygenasesIBA 01/2022 - 01/2015
5	Long Noncoding RNAIBA 01/2021 - 01/2017
5	ChemokinesIBA 01/2021 - 01/2014
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 11/2010
5	Small Interfering RNA (siRNA)IBA 02/2017 - 01/2011
4	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
4	CytokinesIBA 01/2021 - 04/2015
3	Oxygen (Dioxygen)IBA 06/2021 - 06/2011
3	Therapeutic UsesIBA 01/2021 - 10/2011
3	Histone Deacetylase InhibitorsIBA 02/2012 - 06/2011
2	Oncogene Proteins (Oncogene Protein)IBA 03/2022 - 11/2013
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2011
2	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2021
2	enhanced green fluorescent proteinIBA 01/2022 - 07/2012
2	Dihydrotestosterone (Androstanolone)IBA 11/2021 - 01/2020
2	Flame Retardants (Fire Retardants)IBA 08/2021 - 04/2021
2	OrganophosphatesIBA 08/2021 - 04/2021
2	Glucose (Dextrose)FDA LinkGeneric 06/2021 - 06/2011
2	NF-kappa B (NF-kB)IBA 01/2021 - 11/2016
2	OvalbuminIBA 11/2018 - 01/2018
2	Apolipoproteins E (ApoE)IBA 01/2018 - 04/2016
2	jugloneIBA 01/2018 - 08/2013
2	CateninsIBA 01/2018 - 03/2012
2	5'-Nucleotidase (5' Nucleotidase)IBA 01/2018 - 02/2017
2	Pyruvate KinaseIBA 11/2015 - 06/2011
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2015 - 07/2014
2	Transcription Factors (Transcription Factor)IBA 02/2015 - 12/2012
2	Poloxamer (Poloxamer 407)IBA 01/2015 - 08/2013
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2014 - 11/2010
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2014 - 05/2013
2	Protein Isoforms (Isoforms)IBA 11/2013 - 06/2011
2	erucylphosphocholineIBA 01/2013 - 07/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2013 - 07/2012
2	Taurine FDA Link 05/2012 - 11/2010
2	Histone Deacetylases (Histone Deacetylase)IBA 02/2012 - 06/2011
2	Valproic Acid (Depakote)FDA LinkGeneric 02/2012 - 06/2011
2	Histones (Histone)IBA 06/2011 - 06/2011
1	artemisinin (artemisinine)IBA 11/2022
1	artenimol (dihydroartemisinin)IBA 11/2022
1	PlasminogenIBA 03/2022
1	Tumor Biomarkers (Tumor Markers)IBA 03/2022
1	Nicorandil (SG 75)IBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2022
1	Methionine (L-Methionine)FDA Link 01/2022
1	Clodronic Acid (Clodronate)IBA 01/2022
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2022
1	CXC ChemokinesIBA 01/2022
1	Small Cytoplasmic RNAIBA 01/2022
1	HexosesIBA 01/2022
1	LigandsIBA 01/2022

Therapy/Procedure

15	Therapeutics 06/2022 - 08/2011
11	Drug Therapy (Chemotherapy) 01/2022 - 02/2012
4	Radiotherapy 01/2022 - 01/2019
4	Immunotherapy 01/2022 - 01/2019